Abstract
Bisphosphonates are standard treatment for cancer-induced bone disease, a common feature of many advanced malignancies. Traditionally used to inhibit bone turnover and reduce the risk of skeletal-related events, there is now increasing pre-clinical evidence that these agents may also affect tumour burden and disease progression. In particular, combining bisphosphonates with chemotherapeutic agents has been demonstrated to cause substantially increased anti-tumour effects compared to giving the single agents. Clinical studies are in progress to determine whether adding bisphosphonates to standard anti-cancer therapy results in improved outcome for patients. Here we give an overview of the key pre-clinical studies of anti-tumour effects of bisphosphonates, alone and in combination with other agents, and introduce some of the ongoing clinical trials that aim to determine the clinical relevance of bisphosphonates in combination therapy.
Keywords: Zoledronic acid, metastatic bone disease, synergy, bone, Combined Therapies, Bone Disease, Bisphosphonates, advanced malignancies, chemotherapeutic agents, synergy, bone, kidney, prostate, lytic and sclerotic elements, anti-scaling agents, Paget's disease, cholesterol, post-translational modification, osteoclast activity, anti-cancer agents, umour cell apoptosis, MB-231, MCF-7, Hs 578T, alendronate, ibandronate, pamidronate, risedronate, bovine cortical bone slices, cervical intraepithelial neoplasia, lung cancer cells, tumour vascularisation, anti-tumourigenic, osteolytic lesions, non-bone metastases, prostate cancer, zole-dronic acid, T-cell leukemia, regulating tumour growth, COMBINATION THERAPY, invasive cancer, doxorubicin, chemotherapeutic agent, prostate cancer cell lines, mouse breast cancer, intra-cardiac injection, osteolytic bone disease, anatomical, invasive breast cancer, angiogenesis, neo-adjuvant anthracycline, antitumour effects
Current Pharmaceutical Design
Title: Combined Therapies of Bone Disease with Bisphosphonates
Volume: 16 Issue: 27
Author(s): S. P. Syddall, P. D. Ottewell and I. Holen
Affiliation:
Keywords: Zoledronic acid, metastatic bone disease, synergy, bone, Combined Therapies, Bone Disease, Bisphosphonates, advanced malignancies, chemotherapeutic agents, synergy, bone, kidney, prostate, lytic and sclerotic elements, anti-scaling agents, Paget's disease, cholesterol, post-translational modification, osteoclast activity, anti-cancer agents, umour cell apoptosis, MB-231, MCF-7, Hs 578T, alendronate, ibandronate, pamidronate, risedronate, bovine cortical bone slices, cervical intraepithelial neoplasia, lung cancer cells, tumour vascularisation, anti-tumourigenic, osteolytic lesions, non-bone metastases, prostate cancer, zole-dronic acid, T-cell leukemia, regulating tumour growth, COMBINATION THERAPY, invasive cancer, doxorubicin, chemotherapeutic agent, prostate cancer cell lines, mouse breast cancer, intra-cardiac injection, osteolytic bone disease, anatomical, invasive breast cancer, angiogenesis, neo-adjuvant anthracycline, antitumour effects
Abstract: Bisphosphonates are standard treatment for cancer-induced bone disease, a common feature of many advanced malignancies. Traditionally used to inhibit bone turnover and reduce the risk of skeletal-related events, there is now increasing pre-clinical evidence that these agents may also affect tumour burden and disease progression. In particular, combining bisphosphonates with chemotherapeutic agents has been demonstrated to cause substantially increased anti-tumour effects compared to giving the single agents. Clinical studies are in progress to determine whether adding bisphosphonates to standard anti-cancer therapy results in improved outcome for patients. Here we give an overview of the key pre-clinical studies of anti-tumour effects of bisphosphonates, alone and in combination with other agents, and introduce some of the ongoing clinical trials that aim to determine the clinical relevance of bisphosphonates in combination therapy.
Export Options
About this article
Cite this article as:
P. Syddall S., D. Ottewell P. and Holen I., Combined Therapies of Bone Disease with Bisphosphonates, Current Pharmaceutical Design 2010; 16 (27) . https://dx.doi.org/10.2174/138161210793563590
DOI https://dx.doi.org/10.2174/138161210793563590 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Strategies in Therapeutic Applications of Toxoplasmosis: Recent Advances in Liposomal Vaccine Delivery Systems
Current Drug Targets Flavonoid-Based Cancer Therapy: An Updated Review
Anti-Cancer Agents in Medicinal Chemistry Antitumoral-Lipid-Based Nanoparticles: a Platform for Future Application in Osteosarcoma therapy
Current Pharmaceutical Design Inhibition of Autophagy by Targeting ATG4B: Promises and Challenges of An Emerging Anti-cancer Strategy
Clinical Cancer Drugs ADAM Metalloproteinases as Potential Drug Targets
Current Medicinal Chemistry Molecular Mechanisms of Anti-cancer Activities of β-elemene: Targeting Hallmarks of Cancer
Anti-Cancer Agents in Medicinal Chemistry Deep Penetration of Nanoparticulate Drug Delivery Systems into Tumors: Challenges and Solutions
Current Medicinal Chemistry From Bortezomib to other Inhibitors of the Proteasome and Beyond
Current Pharmaceutical Design Cellular Systems Biology Profiling Applied to Cellular Models of Disease
Combinatorial Chemistry & High Throughput Screening HSP90 Inhibitors: Current Development and Potential in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Dual Roles of Sulforaphane in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Radiolabelled Peptides: Eon in Radiopharmaceutical
Current Radiopharmaceuticals Challenges and Successes Using Nanomedicines for Aerosol Delivery to the Airways
Current Gene Therapy Diverse Roles of GADD45α in Stress Signaling
Current Protein & Peptide Science Ewing Sarcoma Family Tumors: Past, Present and Future Prospects
Current Cancer Therapy Reviews Editorial: (Thematic Issue: Nanofluidics and Microfluidics: Novel Approaches in Biomedical Science)
Current Proteomics Applied Proteomics in Companion Animal Medicine
Current Proteomics Bone Disruption and Environmental Pollutants
Endocrine, Metabolic & Immune Disorders - Drug Targets The Holy Grail of Polymer Therapeutics for Cancer Therapy: An Overview on the Pharmacokinetics and Bio Distribution
Current Drug Metabolism Small Molecular Inhibitors Targeting Chromatin Regulating Proteins for Cancer
Current Protein & Peptide Science